PMID- 28569236
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2152-6575 (Print)
IS  - 2152-6567 (Linking)
VI  - 1
IP  - 2
DP  - 2010 Apr 1
TI  - Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination 
      with an intranasal corticosteroid in seasonal allergic rhinitis.
PG  - 14
LID - 10.2500/aap.2010.31.3326 [doi]
AB  - The combination of intranasal antihistamines and intranasal corticosteroids 
      results in superior relief of seasonal allergic rhinitis (SAR) symptoms compared 
      with monotherapy. This study was designed to evaluate the safety and efficacy of 
      olopatadine hydrochloride nasal spray, 0.6% (OLO), administered in combination 
      with fluticasone nasal spray, 50 micrograms (FNS), relative to azelastine nasal 
      spray, 0.1% (AZE), administered in combination with FNS in the treatment of SAR. 
      This was a multicenter, double-blind, randomized, parallel-group comparison of 
      OLO + FNS versus AZE + FNS administered for 14 days to patients >/=12 years of age 
      with histories of SAR. Efficacy assessments recorded by patients in a daily diary 
      included nasal symptom scores. Safety was evaluated based on adverse events 
      (AEs). Pretreatment values for reflective total nasal symptoms scores (rTNSS) 
      were similar for both treatment groups. The mean (SD) 2-week average rTNSS was 
      4.28 (2.63) for OLO + FNS and 4.15 (2.63) for AZE + FNS; these scores were not 
      statistically different between treatment groups. No significant differences (p > 
      0.05) between OLO + FNS and AZE + FNS were observed for the average 2-week 
      percent changes from baseline in rTNSS or in the individual nasal symptoms (nasal 
      congestion, rhinorrhea, itchy nose, and sneezing). Compared with baseline, both 
      groups had statistically significant improvement in rTNSS (p < 0.05). No serious 
      AEs were reported in either group during the study period. Overall, 19 AEs were 
      reported in the OLO + FNS group and 29 AEs were reported in the AZE + FNS group. 
      OLO, when administered adjunctively with FNS, is effective, safe, and 
      well-tolerated in patients with SAR.
FAU - LaForce, Craig F
AU  - LaForce CF
FAU - Carr, Warner
AU  - Carr W
FAU - Tilles, Stephen A
AU  - Tilles SA
FAU - Chipps, Bradley E
AU  - Chipps BE
FAU - Storms, William
AU  - Storms W
FAU - Meltzer, Eli O
AU  - Meltzer EO
FAU - Edwards, Michael
AU  - Edwards M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Allergy Rhinol (Providence)
JT  - Allergy & rhinology (Providence, R.I.)
JID - 101570968
EDAT- 2010/04/01 00:00
MHDA- 2010/04/01 00:01
CRDT- 2017/06/02 06:00
PHST- 2017/06/02 06:00 [entrez]
PHST- 2010/04/01 00:00 [pubmed]
PHST- 2010/04/01 00:01 [medline]
AID - 10.2500/aap.2010.31.3326 [doi]
PST - ppublish
SO  - Allergy Rhinol (Providence). 2010 Apr 1;1(2):14. doi: 10.2500/aap.2010.31.3326.